Aerovate Therapeutics (NASDAQ:JBIO) Upgraded to Buy at Guggenheim

Guggenheim upgraded shares of Aerovate Therapeutics (NASDAQ:JBIO) from a neutral rating to a buy rating in a report issued on Monday morning, MarketBeat.com reports. The firm currently has $14.00 target price on the stock.

Separately, Wall Street Zen upgraded shares of Aerovate Therapeutics to a “hold” rating in a research report on Saturday.

Aerovate Therapeutics Stock Up 3.4%

Shares of NASDAQ JBIO opened at $6.99 on Monday. Aerovate Therapeutics has a 52-week low of $6.57 and a 52-week high of $105.00. The company has a market capitalization of $5.88 million, a price-to-earnings ratio of -0.12 and a beta of 0.93.

About Aerovate Therapeutics

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.